ELCC 2026 Highlights Webinar
Webinar | English | 2025 | 1 hour
Availability
Registration Required
Expires on May 15, 2026
Online Meeting
Apr 15, 2026 8:30 AM - 10:00 AM MST
Cost
$0.00
Credit Offered
1 ACCME Credit
1 Certificate of Attendance Credit

The European Lung Cancer Congress (ELCC) 2026 Highlights Webinar will provide an expert overview of the most impactful research and clinical updates presented at ELCC. This session will highlight key advances in the biology, prevention, early detection, diagnosis, and multidisciplinary management of thoracic malignancies. Faculty will review emerging data from translational and clinical studies and discuss evolving approaches in lung cancer screening, precision medicine, surgical and non-surgical treatment strategies, systemic therapies, and supportive care. Join us for a curated discussion of the findings most likely to influence clinical practice and future research.

Live Activity Date: April 15, 2026 from 9:00-10:15 a.m. MT
This activity is designed for multidisciplinary teams of medical oncologists, surgical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, radiologists and interventional radiologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician associates globally.
Upon completion of this activity, the participants should be able to: 

  • Summarize the latest clinical data on KRAS, EGFR, and HER2-targeted therapies in lung cancer and their implications for treatment selection.
  • Evaluate recent advances in small cell lung cancer (SCLC) management and the emerging role of antibody-drug conjugates (ADCs).
  • Discuss new developments in immunotherapy and treatment strategies for early-stage lung cancer.
Moderators:
  • Alona Zer, MD; Head, Department of Medical Oncology at Rambam Health Care Campus, Haifa District, Israel
  • Helena Linardou, MD, PhD; Director of the 4th Oncology Department and the Comprehensive Clinical Trials Center at Metropolitan Hospital; Athens, Greece 

Speakers:
  • Adrian Sacher, MD; Thoracic Oncologist & Affiliate Scientist at the Princess Margaret Cancer Centre, Ontario, Canada
  • Giannis Mountzios, MD, PhS; 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, Athens, Greece
  • Prof. Jarushka Naidoo; Consultant Medical Oncologist at Beaumont RCSI Cancer Centre, Dublin, Ireland
  • Antonio Passaro, MD, PhD; Medical Oncologist at the Division of Thoracic Oncologist of the European Institute of Oncology, Milan, Italy.    
To be determined
Full Legal Name Commercial Interest Role Level of Participation in the Activity
Alona Zer, MD 1. AstraZeneca, Beigene, Pfizer, MSD, BI, Bayer 1. Consultant Moderator
Helena Linardou, MD, PhD 1. Roche, Pfizer, Astra Zeneca, Abbvie, MSD, BMS, GSK, Novartis, Genesis, Takeda
2. Pfizer, Astra Zeneca, MSD, BMS, GSK, Roche, Novartis
1. Researcher (PI or Named Investigator)
2. Advisor
Moderator
Giannis Mountzios, MD, PhS 1. Amgen, AstraZeneca, BMS, MSD, Novartis, Roche, GSK, Takeda, Summit Therapeutics, Pfizer,
Merck, Daiitsi Sankyo, Gilead
2. Amgen, AstraZeneca, BMS, MSD, Novartis, Roche, GSK, Takeda, Summit Therapeutics, Pfizer, Merck, Daiitsi Sankyo, Gilead
1. Consultant
2. Advisor
Speaker

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."
Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Live Activity Credit

To successfully earn credit, participants must complete the activity during the valid credit period that is notes on the title page. Follow these steps to earn CME/CE Credit*

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Participate in the activity.
  3. Complete the activity evaluation to provide feedback for future programs and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

* The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email: education@iaslc.org.
Powered By